Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jan. 31, 2025	Apr. 30, 2024
Current assets:
Cash and cash equivalents	$ 167,288	$ 31,789
Marketable securities	85,915	178,612
Research and development tax credit receivable	7,485	8,439
Prepaid expenses and other current assets	6,671	6,850
Total current assets	267,359	225,690
Property and equipment, net	1,807	2,227
Right of use assets	5,440	6,920
Other assets	1,387	567
Total assets	275,993	235,404
Current liabilities:
Accounts payable	5,856	9,107
Accrued expenses	18,315	12,398
Lease liability - current portion	1,444	1,302
Total current liabilities	25,615	22,807
Long-term liabilities:
Lease liability - net of current portion	4,338	6,015
Deferred royalty obligation	100,914
Total long-term liabilities	105,252	6,015
Commitments and contingencies (Note 6)
Stockholders’ equity
Common stock, $0.001 par value, 100,000,000 authorized Shares issued and outstanding: 49,493,210 at January 31, 2025 and 42,521,975 at April 30, 2024	49	42
Additional paid-in capital	748,231	679,754
Accumulated deficit	(600,946)	(469,726)
Accumulated other comprehensive loss	(2,208)	(3,488)
Total stockholders’ equity	145,126	206,582
Total liabilities and stockholders’ equity	$ 275,993	$ 235,404